Literature DB >> 8646436

Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis.

C Bologna1, P Viu, C Jorgensen, J Sany.   

Abstract

The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment: before 65 yr (group 1, n = 416) and after 65 yr (group 2, n = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (P = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646436     DOI: 10.1093/rheumatology/35.5.453

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  14 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

Review 3.  Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.

Authors:  Susan M Goodman
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 4.  Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Authors:  Catherine J Lucas; Simon B Dimmitt; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

5.  Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.

Authors:  Biljana Jekic; Ljiljana Lukovic; Vera Bunjevacki; Vera Milic; Ivana Novakovic; Tatjana Damnjanovic; Jelena Milasin; Branka Popovic; Nela Maksimovic; Nemanja Damjanov; Goran Radunovic; Ljiljana Kovacevic; Maja Krajinovic
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

6.  [Is the treatment response in elderly patients with rheumatoid arthritis diminished? Results of a prospective study over 3 months].

Authors:  C Fiehn; S Kessler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

7.  Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.

Authors:  M Hoekstra; A E van Ede; C J Haagsma; M A F J van de Laar; T W J Huizinga; M W M Kruijsen; R F J M Laan
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 8.  Rheumatoid arthritis in the elderly in the era of tight control.

Authors:  Martin Soubrier; Zuzana Tatar; Marion Couderc; Sylvain Mathieu; Jean-Jacques Dubost
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 9.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Authors:  Sandeep K Agarwal; Roberta J Glass; Nancy A Shadick; Jonathan S Coblyn; Ronald J Anderson; Nancy E Maher; Michael E Weinblatt; Daniel H Solomon
Journal:  J Rheumatol       Date:  2008-07-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.